Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 2/20 | 0.70 |
| ▸ | SNCA | P37840 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | MB | P02144 | 1/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.57 |
| ▸ | CA3 | P07451 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RARG | P13631 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16677959 | 0.90 | NQO2 (0.84) | NQO2SNCANPC1RAB9ATP53 | |
| SCHEMBL4085808 | 0.87 | SNCA (0.64) | NQO2SNCANPC1RAB9ATP53 | |
| SCHEMBL5973851 | 0.86 | NPC1 (0.65) | NPC1RAB9ATP53KMT2AMEN1 | |
| SCHEMBL6881442 | 0.85 | NPC1 (0.73) | NQO2SNCANPC1RAB9ATP53 | |
| SCHEMBL715515 | 0.82 | NQO2 (1.00) | NQO2SNCANPC1RAB9ATP53 | |
| SCHEMBL17849584 | 0.81 | MEN1 (0.71) | NQO2SNCANPC1RAB9ATP53 | |
| SCHEMBL10149367 | 0.81 | NPC1 (0.73) | NQO2SNCANPC1RAB9ATP53 | |
| SCHEMBL22067843 | 0.81 | TP53 (0.77) | NQO2SNCANPC1RAB9ATP53 | |
| SCHEMBL17577074 | 0.80 | CACNA1B (0.64) | NQO2SNCANPC1RAB9ATP53 | |
| SCHEMBL22192261 | 0.80 | NQO2 (0.68) | NQO2SNCANPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915337-A4 | HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME | AMOREPACIFIC CORP (KR) | 2009-04-22 | — | — | EP | disclosed |
| US-20080280989-A1 | Hydroxybenzamide Derivatives, the Method For Preparing Thereof and the Cosmetic Composition Containing the Same | AMOREPACIFIC CORPORATION (KR) | 2008-11-13 | — | — | US | disclosed |
| CN-101243042-A | Hydroxybenzamide derivatives, the method for preparing thereof and the cosmetic composition containing the same | AMOREPACIFIC CORP (KR) | 2008-08-13 | — | — | CN | disclosed |
| EP-1915337-A1 | HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME | Amorepacific Corporation (KR) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007021067-A1 | HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280989-A1 | Hydroxybenzamide Derivatives, the Method For Preparing Thereof and the Cosmetic Composition Containing the Same | H1-0, HAAO, H1-10 | NQO2 413/4885SNCA 569/4885NPC1 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.